BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
65.64
+0.28 (0.43%)
At close: Mar 9, 2026, 4:00 PM EDT
64.33
-1.31 (-2.00%)
After-hours: Mar 9, 2026, 5:38 PM EDT
BridgeBio Pharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 12,725 | 14,740 | 5,186 | 7,023 | 1,139 | 2,455 | |
| Market Cap Growth | 81.79% | 184.24% | -26.16% | 516.57% | -53.61% | -71.83% | |
| Enterprise Value | 13,942 | 15,964 | 6,661 | 8,229 | 2,271 | 3,264 | |
| Last Close Price | 65.36 | 76.49 | 27.44 | 40.37 | 7.62 | 16.68 | |
| PS Ratio | 25.23 | 29.36 | 23.37 | 754.92 | 14.67 | 35.22 | |
| PB Ratio | - | -7.10 | -3.56 | -5.23 | -0.91 | -2.84 | |
| EV/Sales Ratio | 27.77 | 31.80 | 30.02 | 884.51 | 29.25 | 46.81 | |
| Debt / Equity Ratio | -0.90 | -0.90 | -1.19 | -1.30 | -1.38 | -1.99 | |
| Net Debt / Equity Ratio | -0.61 | -0.61 | -0.72 | -0.97 | -1.00 | -1.03 | |
| Net Debt / EBITDA Ratio | -2.57 | -2.57 | -1.84 | -2.20 | -2.71 | -1.57 | |
| Net Debt / FCF Ratio | -2.85 | -2.85 | -2.01 | -2.47 | -2.95 | -1.74 | |
| Asset Turnover | 0.54 | 0.54 | 0.30 | 0.02 | 0.10 | 0.08 | |
| Quick Ratio | 2.52 | 2.52 | 4.44 | 3.04 | 4.03 | 6.34 | |
| Current Ratio | 2.77 | 2.77 | 4.67 | 3.32 | 4.52 | 6.58 | |
| Return on Assets (ROA) | -33.83% | -33.83% | -49.24% | -64.08% | -35.80% | -41.75% | |
| Return on Capital Employed (ROCE) | -77.50% | -77.50% | -75.50% | -148.90% | -93.40% | -65.30% | |
| Earnings Yield | -5.72% | -4.92% | -10.33% | -9.16% | -42.24% | -22.91% | |
| FCF Yield | -3.53% | -3.03% | -10.06% | -7.53% | -37.25% | -20.82% | |
| Buyback Yield / Dilution | -2.93% | -2.93% | -14.30% | -10.39% | -2.16% | -22.34% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.